- Home
- IMTX
IMTX
Immatics N.V.
as 04-18-2025 1:38pm EST
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
| Founded: | N/A | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 514.2M | IPO Year: | N/A |
| Target Price: | $16.67 | AVG Volume (30 days): | 849.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.30 - $13.77 | Next Earning Date: | 05-13-2025 |
| Revenue: | $161,336,577 | Revenue Growth: | 188.60% |
| Revenue Growth (this year): | -56.95% | Revenue Growth (next year): | 18.80% |
Latest Immatics N.V. News
IMTX Breaking Stock News: Dive into IMTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
22 days ago
Immatics Full Year 2024 Earnings: Beats Expectations
GlobeNewswire
23 days ago
Immatics Announces Full Year 2024 Financial Results and Business Update
Simply Wall St.
2 months ago
Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year
Simply Wall St.
5 months ago
Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
TipRanks
5 months ago
Immatics Sees Revenue Surge Despite R&D Expenses
GlobeNewswire
5 months ago
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
GlobeNewswire
5 months ago
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Simply Wall St.
6 months ago
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50%
Compare IMTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMTX Immatics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.